Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

First Generic Approvals Decline For Fourth Straight Year At US FDA

Executive Summary

Blemish in otherwise record-setting performance could simply be a result of coalescing variables, but it robs the agency of an easy pricing message.

Advertisement

Related Content

Drug Pricing Bill May Make Six-Month ANDA Review Slower Than Eight-Month Review
ANDA Backlog: FDA Climbs The Mountain, Will Need To Climb It Again
Review Voucher Program For Rare Pediatric Diseases Should Not Be Reauthorized, US FDA Says
GDUFA II: Priority Reviews Considered For Some ANDAs
Patent Cliff Continues in 2014, But Not So Steeply

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS120120

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel